Tandem Diabetes Care (TNDM) FCF Margin (2013 - 2026)
Tandem Diabetes Care (TNDM) posted FCF Margin of 1.94% for Q1 2026, up 81.11% on a QoQ basis from 1.07% in Q4 2025, and up 1100.0% year-over-year from 0.16% in Q1 2025.
Tandem Diabetes Care (TNDM) FCF Margin (2013 - 2026) Analysis & Trends
Tandem Diabetes Care's FCF Margin history runs 14 years deep, the most recent figure standing at 1.94% for Q1 2026.
- Quarterly FCF Margin rose 1100.0% year-over-year to 1.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.35% (down 189.0% YoY) and the FY2025 annual result came in at 2.92%, down 560.0% from the prior year.
- FCF Margin was 1.94% for Q1 2026 at Tandem Diabetes Care, up from 1.07% in the prior quarter.
- Across five years, FCF Margin topped out at 11.85% in Q3 2022 and bottomed at 16.03% in Q1 2023.
- A 5-year average of 0.1% and a median of 1.07% in 2025 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin tumbled 2355 bps — and 2024, when it soared 1437 bps.
- Tandem Diabetes Care's FCF Margin stood at 2.53% in 2022, then tumbled by 280 bps to 4.55% in 2023, then soared by 316 bps to 9.83% in 2024, then slumped by 89 bps to 1.07% in 2025, then jumped by 81 bps to 1.94% in 2026.
- Business Quant data shows TNDM's FCF Margin at 1.94% in Q1 2026, 1.07% in Q4 2025, and 1.58% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -1.28% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 37.67% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.68% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.18% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Tandem Diabetes Care | 1.16 Bn | 587.46 Mn | 136.79 Mn | 1.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.94% |
| Dec 31, 2025 | 1.07% |
| Sep 30, 2025 | -1.58% |
| Jun 30, 2025 | -3.16% |
| Mar 31, 2025 | -9.06% |
| Dec 31, 2024 | 9.83% |
| Sep 30, 2024 | 8.83% |
| Jun 30, 2024 | -5.85% |
| Mar 31, 2024 | -5.85% |
| Dec 31, 2023 | -4.55% |
| Sep 30, 2023 | 8.10% |
| Jun 30, 2023 | -6.99% |
| Mar 31, 2023 | -16.03% |
| Dec 31, 2022 | 2.53% |
| Sep 30, 2022 | 11.85% |
| Jun 30, 2022 | 3.11% |
| Mar 31, 2022 | 7.51% |
| Dec 31, 2021 | 8.93% |
| Sep 30, 2021 | 19.01% |
| Jun 30, 2021 | 16.70% |